Federal Register / Vol. 88, No. 200 / Wednesday, October 18, 2023 / Notices 71867 

CRITERIA FOR INCLUSION/EXCLUSION OF STUDIES IN THE REVIEW

Domain Inclusion Exclusion 

Population .................. • Publications that address quality of care indicators, criteria, or benchmarks. We will 

accept the authors’ definition of quality of care. Quality indicators may include care 

processes-related measures (e.g., follow-up post discharge, continuity of care, 

medication errors), heath services utilization measures (e.g., hospital readmission, 

emergency department visit), care satisfaction (e.g., patient satisfaction, care needs 

met, trust in care provider), or health outcomes (e.g., mortality, physical functional 

status, mental functioning, quality of life) used as quality indicators. Publications 

that do not address quality of care in detail but include quality of care and health 

equity in a framework will also be eligible. Care disparities may either address differences in provided health services, focus on care services or health outcomes of 

priority populations.

• Publications not addressing 

quality of care and publications not mentioning quality of 

care nor health equity as a 

central feature of a framework. 

Concept ..................... • Publications that include a figure or detailed description of a framework of quality of 

care or care disparities; frameworks may use the format of a logic model, analytic 

framework, conceptual model, or other conceptualizations of quality of care.

• Publications citing existing 

frameworks without further 

conceptual contribution to the 

framework and publications 

describing only the need of 

quality of care measures. 

Context ...................... • Healthcare, specifically healthcare delivery organizations .......................................... • Studies in contexts outside of 

healthcare or not specific to 

healthcare. 

Other limiters ............. • Reports published in English-language, journal manuscripts, trial records, and gray 

literature in the public domain from the outlined sources.

• Data reported in abbreviated 

format (e.g., conference abstracts) will be excluded; 

studies not published in 

English 

• Systematic reviews will be retained for reference mining. 

Dated: October 12, 2023. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2023–22915 Filed 10–17–23; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 5 U.S.C. 

Section1009(d), notice is hereby given 

of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)- 

CE24–013, Research Grants to Identify 

Effective Community-Based Strategies 

for Overdose Prevention (R01). 

Date: March 12–13, 2024. 

Time: 8:30 a.m.–5 p.m., EDT. 

Place: Web Conference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Aisha L. Wilkes, M.P.H., Scientific 

Review Officer, National Center for 

Injury Prevention and Control, Centers 

for Disease Control and Prevention, 

4770 Buford Highway NE, Mailstop 

S106–9, Atlanta, Georgia 30341, 

Telephone: (404)639–6473; Email: 

AWilkes@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–23006 Filed 10–17–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

CE24–029, Grants to Support New 

Investigators in Conducting Research 

Related to Preventing Interpersonal 

Violence Impacting Children and Youth. 

Date: March 19, 2024. 

Time: 8:30 a.m.–5 p.m., EDT. 

Place: Web Conference. 

Agenda: To review and evaluate grant 

applications. 


ddrumheller on DSK120RN23PROD with NOTICES1